Here’s what you should know:
1. Judge William Bryson issued the ruling, which will allow generic drugmakers to sell their own versions of Restasis.
2. Allergan was under scrutiny over its decision to transfer Restasis’ patent rights to a Native American tribe. Allergan made the move to protect the drug from administrative review. Allergan said it would not invoke the tribe’s sovereign immunity in court, however.
https://www.beckersasc.com/gastroenterology-and-endoscopy/allergan-under-scrutiny-for-patent-dodging-4-insights.html
3. Restasis accounted for $1.5 billion in Allergan’s sales in 2016. It was more than 10 percent of the company’s revenue.
4. Allergan’s stock tumbled from $205.08 to $192.85 following the news of the judge’s ruling Oct. 16. As of noon Oct. 17, the stock was back trading at $200.
More articles on improving performance:
FDA microbiologists testify during trial on 2012 fungal meningitis outbreak: 5 updates
10 deficiencies AAAASF cites most & how to correct them — No. 2: Universal Precautions, ASC standard 800.42.12
WHO, CDC initiatives aim to boost hand hygiene market: 5 points
